Table 4 Comparison among different age groups

A- Comparison based on targeted VTL achievement frequency (standard doses of 40-60 mg Q6H)

Age groups

% Achieved targeted VTLs

Age groups

% Achieved targeted VTLs

RR (95% CI)

p-value

Gp-II (n = 70)

44.3

Gp-I (n = 45)

31.1

2.24 (0.91, 4.33)

 < 0.05

Gp-I (n = 45)

31.1

Gp-III (n = 55)

18.2

4.31 (1.03, 5.11)

 < 0.001

Gp-IV (n = 58)

58.7

Gp-I (n = 45)

31.1

3.34 (1.25, 7.34)

 < 0.05

Gp-II (n = 70)

44.3

Gp-III (n = 55)

18.2

6.01 (3.23, 8.36)

 < 0.001

Gp-IV (n = 58)

58.7

Gp-II (n = 70)

44.3

3.28 (1.21, 6.59)

 < 0.05

Gp-IV (n = 58)

58.7

Gp-III (n = 55)

18.2

9.85 (5.28, 14.25)

 < 0.001

B- Comparison based on mean VTLs (standard doses of 40-60 mg/day Q6H)

Age groups

VTLs mg/L

(Mean ± SD)

Age groups

VTLs mg/L

(Mean ± SD)

Means difference (95% CI)

p-value

Gp-II (n = 70)

11.3 ± 1.2

Gp-I (n = 45)

10.2 ± 0.6

1.72 (2.12, 2.97)

0.023

Gp-I (n = 45)

10.2 ± 0.6

Gp-III (n = 55)

10.1 ± 0.2

1.98 (1.75, 2.66)

0.451

Gp-IV (n = 58)

12.4 ± 2.1

Gp-I (n = 45)

10.2 ± 0.6

0.86 (- 1.28, 3.88)

0.021

Gp-II (n = 70)

11.3 ± 1.2

Gp-III (n = 55)

10.1 ± 0.2

2.88 (1.55, 5.55)

0.011

Gp-II (n = 70)

11.3 ± 1.2

Gp-IV (n = 58)

12.4 ± 2.1

2.66 (2.04, 2.80)

0.032

Gp-IV (n = 58)

12.4 ± 2.1

Gp-III (n = 55)

10.1 ± 0.2

1.65 (1.54, 2.65)

0.005

C- Comparison based on mean VTLs (higher doses/day Q6H)

Age groups

VTLs mg/L

(Mean ± SD)

Age groups

VTLs mg/L

(Mean ± SD)

Means difference (95% CI)

p-value

Gp-II (n = 39)

12.3 ± 2.1

Gp-I (n = 31)

11.1 ± 0.9

2.23 (2.10, 3.14)

0.025

Gp-I (n = 31)

11.1 ± 0.9

Gp-III (n = 45)

10.4 ± 0.2

1.88 (1.66, 3.44)

0.041

Gp-IV (n = 24)

12.8 ± 1.3

Gp-I (n = 31)

11.1 ± 0.9

0.82 (- 1.31, 3.44)

0.034

Gp-II- (n = 39)

12.3 ± 2.1

Gp-III (n = 39)

10.4 ± 0.2

2.31 (1.52, 5.75)

0.031

Gp-II (n = 39)

12.3 ± 2.1

Gp-IV (n = 24)

12.8 ± 1.3

2.13 (2.02, 2.17)

0.065

Gp-IV (n = 24)

12.8 ± 1.3

Gp-III (n = 39)

10.4 ± 0.2

1.48 (1.23, 2.09)

0.026